Depression und Angststörungen — Epidemiologie, theoretische Konzepte und Therapiemöglichkeiten bei Komorbidität

  • R. J. Boerner
  • H. J. Möller
Conference paper


Die häufige klinische Beobachtung des gemeinsamen Auftretens von Depression (Major-Depression) und Angststörungen führte zu einigen Überlegungen bzw. Forschungsarbeiten hinsichtlich der Epidemiologie des Verlaufs und Therapie dieser komorbiden Angststörung.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agras SW, Silvester D, Oliveau D (1969) The epidemiology of common fears and phobias. Comprehensive Psychiatry 10: 439–447CrossRefGoogle Scholar
  2. Albus M, Scheibe G (1993) Outcome of panic disorder with or without concomitant depres-sion: a 2-year prospective follow-up study. Am J Psychiatry 150: 12:1878–1880PubMedGoogle Scholar
  3. Angst J, Dobler-Mikola A (1985) The Zurich study-V. Anxiety and phobia in young adults. Euro Arch Psychiatry Neurol Sci 234: 408–418CrossRefGoogle Scholar
  4. Asnis M, van Praag HM (1995) Panic disoder. Clinical, Biological and Treatment Aspects. The EinsteinPsychiatrySeriesWiley-Publication, New York, ChichesterGoogle Scholar
  5. Ballenger IC (1990) Clinical Aspects of Panic Disorder. Wiley-Liss, New YorkGoogle Scholar
  6. Bacal B, Amarilho IP do, Zamijovski M, Lion MF (1969) Doxepin action on neurotic patients with cardiac symptomatology. Hospital 76: 1739–1748Google Scholar
  7. Benkert O, Hautzinger M (1995) Mitteilung über die Ergebnisse einer Studie im Vergleich Moclobemid und VT der Panikstörung. AGPN-Kongress, NürnbergGoogle Scholar
  8. Berger PM (1991) Moclobemide in Panic Disorder. An Open finding Study. 5th World Congress of Biological Psychiatry, FlorenceGoogle Scholar
  9. Berwish N, Amsterdam J (1989) An overview of investigational antidepressants. Psychosomatics 30: 1–17PubMedGoogle Scholar
  10. Boerner RI (1995a) Integrative Behandlungsstrategien bei Panikstörung mit Agoraphobie sowie depressiver Störung. Nervenarzt 66: 3: 212–217Google Scholar
  11. Boerner RI (1995b) Therapieresistente Panikstörung - Erfolg einer Kombination mit Imipramin, Moclobemid und VT. Psychiatrische Praxis 221: 30–33Google Scholar
  12. Boerner RI, Möller HJ (1996) Pharmakotherapie der Panikstörung und oder Agoraphobie - Leitlinien und klinische Anwendungsstrategien. Psychopharmakotherapie 3: 4:168–178Google Scholar
  13. Boerner RI (1996) Buspiron in der Therapie der generalisierten Angststörung mit Alkoholmißbrauch und Agoraphobie. Nervenheilkunde 15: 454–458Google Scholar
  14. Boerner RI, Gülsdorff B, Margraf J, Osterheider M, Wittchen HU, Philipp M (1997) Die Panikstörung - Diagnose und Behandlung. Schattauer VerlagGoogle Scholar
  15. Boerner RJ, Möller HJ (1997a) The Clinical Benefit of Serotonin Reuptake Inhibitors (SSRI) in the Treatment of Panic Disorders with and without Agoraphobia. International Journal of Psychiatry in Clinical PracticeGoogle Scholar
  16. Boerner RJ, Möller HJ (1997b) Pharmakotherapie der sozialen Phobie. akzeptiert in der NervenheilkundeGoogle Scholar
  17. Boerner RI, Möller HJ (1997c) Therapie-Non-Response und Therapie-Resistenz bei Angststörungen: Definitionsmerkmale und Therapiemöglichkeiten. akzeptiert in der NervenheilkundeGoogle Scholar
  18. Boerner RJ, Möller HJ (1997d) Zum Stellenwert von Kombinationstherapien bei # Angststörungen. Akzeptiert in der NervenheilkundeGoogle Scholar
  19. Boyer W (1994) Serotonin uptake inhibitors are superior to imipramine in alleviating panic attacks. A meta-analysis. In: Darcourt G, Mendlewicz J, Racagni G, Brunello N (eds.). Current therapeutic approaches to panic and other anxiety disorders. Int Acad Biomed Drug Res, Karger, Basel 8: 55–60Google Scholar
  20. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in allevia-ting panic attacks: a meta-analysis. I Clin Psychopharmacology 1995; 10: 45–49CrossRefGoogle Scholar
  21. Bronisch T, Hecht H (1990) Major depression with and without a coexisting anxiety disorder: social dysfunction, social integration, and personality features. J Affect Disord 20: 151–157PubMedCrossRefGoogle Scholar
  22. Brown TA, Antony MM, Barlow DH (1995) Diagnostic Comorbidity in Panic Disorder: Effect on Treatment Outcome and Course of Comorbid Diagnoses Following Treatment. Journal of Consulting and Clinical Psychology 63: 3: 408–418PubMedCrossRefGoogle Scholar
  23. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR (1996) Treatment Outcomes for Primary Care Patients With Major Depression and Lifetime Anxiety Disorders. Am J Psychiatry 153: 1293–1300PubMedGoogle Scholar
  24. Burke MJ, Preskorn SH (1995) Short-Term Treatment of Mood Disorders with Standard Antidepressants. Psychopharmacology 1053–1065Google Scholar
  25. Burnham DB, Steiner M, Gergel IP, Oakes R, Bailer DC, Wheadon DE (1995) Paroxetine longterm safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico; DecemberGoogle Scholar
  26. Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM (1988) Clomipramine for panic disorder. I. The first 10 weeks of a long-term comparison with imipramine. J Affective Dis 14: 123–127CrossRefGoogle Scholar
  27. Charalampous KD, Freemesser GF, Smalling KF (1974) double-blind controlled study of loxapine succinate in the treatment of anxiety neuroses. J Clin Pharmacol 14: 464–469Google Scholar
  28. Charney DS, Woods SW (1989) Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 50: 418–423PubMedGoogle Scholar
  29. Chaudhry MR, Ishaq M, Suelman M (1970) Double-blind study with sinequan (doxepin) vs diazepam vs placebo in psychoneurosis. J Pak Med Assoc 20: 315–319Google Scholar
  30. Clayton P (1990) The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 51: 35–39PubMedGoogle Scholar
  31. Cleary MA, Guy W (1975) Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1: 115–120Google Scholar
  32. Cohn JB, Bowden CL, Fisher JG, Rodos JJ (1986a) Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 80: 10–16CrossRefGoogle Scholar
  33. Cohn JB, Wilcox C (1986b) Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry 47:409–412Google Scholar
  34. Coryell W, Endicott J, Winokur G (1992) Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. Am J Psychiatry 149: 100–107PubMedGoogle Scholar
  35. Cottraux J, Note ID, Cungi C et al. (1995) A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. British J of Psychiatry 167: 635–641CrossRefGoogle Scholar
  36. Cross-National Collaborative Panic Study (1992) Drug Treatment of Panic Disorder. British J of Psychiatry 160: 191–202CrossRefGoogle Scholar
  37. de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R (1995) Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 152: 683–691PubMedGoogle Scholar
  38. DeMartinis NA, Schweizer E, Rickels K (1996) An Open-Label Trial of Nefazodone in High Comorbidity Panic Disorder. J Clin Psychiatry 57: 245–248PubMedGoogle Scholar
  39. Den Boer JA, Westenberg HGM, Kamerbeek WDJ et al. (1987) Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2: 21–32CrossRefGoogle Scholar
  40. Den Boer JA, Westenberg HGM (1988) Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59–74CrossRefGoogle Scholar
  41. Den Boer JA, Sitsen JM (1994) Handbook of Depression and Anxiety. A Biological Approach. Marcel Dekker, Inc. New York Basel Hong KongGoogle Scholar
  42. Dunbar GC, Cohn JB, Fabre LF et al. (1991) A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 159: 394–398PubMedCrossRefGoogle Scholar
  43. Dunbar GC, Fuell DL (1992) The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 6: 4: 81–90PubMedCrossRefGoogle Scholar
  44. Dunbar GC (1995) A double-blind placebo-controlled study of paroxetine and clomipramine in the treatment of panic disorder. Presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, FL, May 23, 1995Google Scholar
  45. Dunner DL, Dunbar GC (1993) Managing the patient with depression and anxiety. Eur Psychiatry 8: 1: 9–12Google Scholar
  46. Enkelman R (1991) Atprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 105: 428–432CrossRefGoogle Scholar
  47. Fabre LF (1987) Double-blind comparison of buspirone with diazepam in anxious patients. Curr Therap Res 41: 751–759Google Scholar
  48. Fabre LF (1990) Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 51: 9: 55–61PubMedGoogle Scholar
  49. Fahy TJ, O’Rourke D, Brophy J, Schazmann W, Sciascia S (1992) The Galway study of panic disorder: clomipramine and lofepramine in DSM III-R panic disorder: a placebo-controlled trial. J Affect Disord 25: 63–75PubMedCrossRefGoogle Scholar
  50. Feighner JP, Merideth CH, Hendrickson GA (1982) A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 43: 103–107PubMedGoogle Scholar
  51. Fielding JM, Mowbray RM, Davies B (1969) Trial of an anti-anxiety compound doxepin (Sinequan). Psychopharmacologia 15: 134–143PubMedCrossRefGoogle Scholar
  52. Gammans RE, Stringfellow JC, Hvizdos AJ et al. (1992) Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-aalysis of eight randomized, controlled studies. Neuropsychobiology 25: 193–201PubMedCrossRefGoogle Scholar
  53. Gentil V, Lotufo-Neto F, Andrade L et al. (1993) Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. J Psychopharmacol 7: 316–324CrossRefGoogle Scholar
  54. Glogen S, Grunhaus L, Gladic D, O’Ryan F, Cozhen L, Codner S (1989) Panic attacks and agora-phobia: low dose clomipramine treatment. J Clin Psychopharmacol 9: 28–32Google Scholar
  55. Gorman J, Liebowitz MR, Fyer AJ et al (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol; 7: 329–332PubMedCrossRefGoogle Scholar
  56. Greenblatt DJ, Shader RI (1974) Benzodiazepines in clinical practice. Raven Press, New YorkGoogle Scholar
  57. Grunhaus L, Harel Y, Krugler T, Pande A, Haskett R (1988) Major depressive disorder and panic disorder. Clin Neuropharmacol 11: 454–461PubMedCrossRefGoogle Scholar
  58. Grunhaus L (1988) Clinical and psychobiological characteristics of simultaneous panic disorder and major depression. Am J Psychiatry 145:1214–1221PubMedGoogle Scholar
  59. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278–296PubMedCrossRefGoogle Scholar
  60. Heimberg RE, Liebowitz MR, Hope DA, Schneier FS (1996) Social phobia. Diagnosis, assessment, and treatment. The Guildford Press, New York, LondonGoogle Scholar
  61. Hoehn-Saric R, McLeod DR, Hipsley PA (1993) Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13: 321–326PubMedCrossRefGoogle Scholar
  62. Hoehn-Saric R, Fawcett J, Munjack DJ, Roy-Byrne PP (1994) A multicentre, double-blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder. Poster on the 19th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Washington DC, Juni 1994Google Scholar
  63. Hoffart A, Due-Madsen J, Lande B, Gude T, Bille H, Torgersen S (1993) Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 54: 481–487PubMedGoogle Scholar
  64. Hudson JI, Pope HG (1990) Affective spectrum disorder: Does antidepressant response iden-tify a family of disorders with a common pathophysiology? Am J Psychiatry 147: 552PubMedGoogle Scholar
  65. Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM (1985) Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 5: 290–296PubMedGoogle Scholar
  66. Janicak P, Davis J, Preskorn S, Ayd F (1993) Principles and practice of psychopharmaco-therapy. Baltimore: Williams and Wilkens 223–240Google Scholar
  67. Joyce PR, Paykel ES (1989) Predictors of drug response in depression. Arch Gen Psychiatry 46: 89–99PubMedGoogle Scholar
  68. Kasich AM (1969) Clinical evaluation of doxepin and diazepam in patients with gastrointestinal disease and anxiety. Psychosomatics 10: 18–20Google Scholar
  69. Kasper S, Möller HJ (1995) Angst-und Panikerkrankungen. Gustav Fischer Verlag, Jena, StuttgartGoogle Scholar
  70. Katschnig H, Amering M (1995) The Long-Term Course of Panic Disorder. Wolfe BE., Maser JD (eds) Treatment of Panic Disorder. A Consensus Development Conference. AP Press, Washington, 73–83.Google Scholar
  71. Keller MB, Lavori PW, Goldenberg I et al. (1993) Influence of depression on the treatment of panic disorder with imipramine, aprazolam und placebo. J Affect Disord 28: 27–38PubMedCrossRefGoogle Scholar
  72. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1992) Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry 49: 716–722PubMedGoogle Scholar
  73. Kessler RC, McGonagle KH, Zhao S et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8–19PubMedGoogle Scholar
  74. Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. psychopharmacologia 5: 397PubMedCrossRefGoogle Scholar
  75. Klerman MD, Gerald L (1992) Treatment for Panic Disorder. J Clin Psychiatry 53: 3: 14–19PubMedGoogle Scholar
  76. Laakmann G, Blaschke D, Hippius H, Messerer D (1986) Wirksamkeits-und Verträglichkeitsvergleich von Alprazolam und Amitriptylin bei der Behandlung von depressiven Patienten in der Praxis des niedergelassenen Allgemein-und Nervenarztes. In: Hippius H (Hrsg) Benzodiazepine - Rückblick und Ausblick. Springer. Berlin Heidelberg New York Tokyo, 139–147Google Scholar
  77. Lecrubier Y (1994) A double-blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. Poster. Congres of the Association of European Psychiatrists (AEP), KopenhagenhGoogle Scholar
  78. Lecrubier Y, Bakker A, Judge R (1995a, accepted) Comparison of paroxetine, clomipramine and placbo in the treatment of panic disorder. ECNPGoogle Scholar
  79. Lecrubier Y, Bakker A, Judge R (1995b, accepted) Long-term evaluation of paroxetine, clomipramine and placebo in panic. ECNPGoogle Scholar
  80. Lepola UM, Koponen H, Leinonen E (1994) Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiaty 27: 186–188CrossRefGoogle Scholar
  81. Lepola UM, Leinonen E, Turtonen J, Pentinen J (1994) The effect of citalopram in panic disorder and agoraphobia: a pilot study. Nord J Psychiatry 48: 13–17CrossRefGoogle Scholar
  82. Liebowitz MR, Quitkin FM, Stewart JW et al. (1984) Phenelzine vs. imipramine in atypical depression. Arch Gen Psychiatry 41: 669–677PubMedGoogle Scholar
  83. Liebowitz MR, Fyer AJ, Gorman JM et al. (1986) Phenelzine in social phobia. J Clin Psychopharmacol 6: 93–98PubMedGoogle Scholar
  84. Liebowitz MR (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 82: 360: 29–34CrossRefGoogle Scholar
  85. Liebowitz MR, Schneier F, Campeas R et al. (1992) Phenelzine vs atenolol in social phobia. Arch Gen Psychiatry 49: 290–300PubMedGoogle Scholar
  86. Margraf J, Schneider S (1993) Panik. 2. Auflage, Springer-Verlag Berlin, Heidelberg, New YorkGoogle Scholar
  87. Margraf J, Barlow DH, Clark DM, Teich MJ (1993) Psychological Treatment of Panic. Work in Progress on Outcome Active Ingredients And Follow-Up. Behav Res Ther 31: 1: 1–8PubMedCrossRefGoogle Scholar
  88. Marks IM, Swinson RP, Basoglu M et al. (1993) Alpraxolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 162: 776–787PubMedCrossRefGoogle Scholar
  89. Merikangas K, Angst J, Eaton W et al. (in press) Comorbidity and boundaries of affective disorders with anxiety disorders and substance abuse: Results of an international task force. Br J PsychiatGoogle Scholar
  90. Montgomery SA (1989) The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 4: 1: 113–119PubMedCrossRefGoogle Scholar
  91. Montgomery SA (1990) Which antidepressant? A review of older treatments. In: Montgomery SA (ed) Anxiety and Depression. Petersfield, Hampshire, United Kingdom: Wrightson Biomedical 31–34Google Scholar
  92. Montgomery SA (1992) The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 6: 4: 91–100PubMedCrossRefGoogle Scholar
  93. Montgomery SA (1995) Selective Serotonin Reuptake Inhibitors in the Acute Treatment of Depression. Psychopharmacology 1043–1051Google Scholar
  94. Montgomery SA, Djäry L (1996) The antidepressant efficacy of citalopram. Int Clin Psycho-pharmacology 11: 1: 29–33CrossRefGoogle Scholar
  95. Munjack DJ, Bruns J, Baltazar PL et al. (1991) A pilot study of buspirone in the treatment of social phobia. J Anx Disord 5: 87–98CrossRefGoogle Scholar
  96. Noyes R, Reich J, Christiansen J, Suelzer M, Pfohl B, Coryell WA (1990) Outcome of Panic Dis-order. Relationship to Diagnostic Subtypes and Comorbidity. Arch Gen Psychiatry 47: 809–818PubMedGoogle Scholar
  97. Noyes R, Burrows GD, Reich JH et al. (1996) Diazepam versus Alprazolam for the Treatment of Panic Disorder. J Clin Psychiatry 57: 8: 349–355PubMedGoogle Scholar
  98. Nutt D, Montgomery SA (1996) Moclobemide in the treatment of social phobia. International Clin Psychopharmacol 3: 77–82CrossRefGoogle Scholar
  99. Oehrberg S, Christiansen E, Behnkek et al. (1995) Paroxetine in the treatment of panic disoder. Randomised Douple-blind, placebo-controlled study. British Journal of Psychiatry 167: 374–379PubMedCrossRefGoogle Scholar
  100. Paykel ES, Parker RR, Rowan PR, Rao BM, Taylor CN (1983) Nosology of atypical depression. Psychol. Med 13:131Google Scholar
  101. Pecknold JC, Matas M, Howarth B, Ross C et al. (1989) Evaluation of buspirone as an anti-anxiety agent: buspirone and diazepam versus placbo. Can J Psych 34: 766–771Google Scholar
  102. Perkonigg A, Wittchen HU (1995) Epidemiologie von Angststörung. In: Kasper S, Möller HJ (Hrsg). Angst-und Panikerkrankungen, Gustav Fischer Verlag, Jena, Stuttgart, 137–156Google Scholar
  103. Pinder RM, Brogden RN, Speight TM, Avery GS (1977) Doxepin up-to-date. A review of ist pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 13: 161–218PubMedCrossRefGoogle Scholar
  104. Potts NLS, Book S, Davidson JRT (1996) The neurobiology of social phobia. International Clin Psychopharmacol u: 3: 43–48CrossRefGoogle Scholar
  105. Reich J, Yates W (1988) A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 145: 590–594PubMedGoogle Scholar
  106. Reiter SR, Pollack MH, Rosenbaum JF et al. (1990) Clonazepam for the treatment of social phobia. J Clin Psychiatry 51: 470–472PubMedGoogle Scholar
  107. Rickels K, Weisman K, Norstad N, Singer M et al. (1982) Buspirone and diazepam in anxiety. a controlled study. J Clin Psychiary 43: 81–86Google Scholar
  108. Rickels K, Schweizer E (1990) The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 10: 3:101–110Google Scholar
  109. Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E (1991) Buspirone in major depression: a controlled study. J Clin Psychiatry 52: 34–38PubMedGoogle Scholar
  110. Robins LN, Regier DA (1991) Psychiatric Disorders in America. The Epidemiologie Catchment Area Studa. New York, Maxwell Maemillan InternationalGoogle Scholar
  111. Ross CA, Matas M (1987) A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can J Psychiatry 50: 884–895Google Scholar
  112. Sanderson WC, Wetzler S (1995) Cognitive Behavioral Treatment of Panic Disorder. In: Asnis M, van Praag HM. Panic Disorder, Clinical, Biological and Treatment Aspects. The EinsteinPsychiatrySeries Wiley-Publication, New York, Chichester 314–337Google Scholar
  113. Schneier FR, Liebowitz MR, Davies SO et al. (1990) Fluoxetine in Panic Disorder. J Clin Psychopharmacology 119–121Google Scholar
  114. Schneier FR, Chin SJ, Hollander E et al. (1992) Fluoxetine in social phobia (letter) J Clin Psychopharmacol 12: 62–63PubMedGoogle Scholar
  115. Schwartz A, Schwartz RM (1993) Depression Theories and Treatments. Psychological, Biological and Social Perspectives. Columbia University Press, New YorkGoogle Scholar
  116. Schweizer E, Rickels K, Hassman H (1994) A double-blind, placebo-controlled comparison of imipramine and buspirone in the treatment of major depression in the elderly in the community. Psychopharmacol Bull 30: 639Google Scholar
  117. Schweizer E, Rickels K, Uhlenhuth EH (1995) Issues in the Long-Term Treatment of Anxiety Disorder. Psychopharmacology 1349–1359Google Scholar
  118. Sellers EM, Ciraulo DA, DuPont RL et al. (1993) Alprazolam and benzodiazepine dependence. J Clin Psychiatry 54: 10: 64–75Google Scholar
  119. Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR (1996) Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 57: 287–291Google Scholar
  120. Sternbach H (1990) Fluoxetine treatment of social phobia (letter) J Clin Psychopharmacol 10: 230PubMedGoogle Scholar
  121. Starand M, Hetta J, Rosen A, Sörensen S et al. (1990) A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 51: 40–45Google Scholar
  122. Tesar GE, Rosenbaum JF, Pollack MH et al. (1991) Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorde. J Clin Psychiatry 52: 69–76PubMedGoogle Scholar
  123. Tiffon L, Coplan JD, Papp LA, Gorman JM (1994) Augmentation Strategies With Tricyclic or Fluoxetine Treatment in Seven Partially Responsive Panic Disorder Patients. J Clin Psychiatry 55: 66–69PubMedGoogle Scholar
  124. Tollefson G, Holman S, Sayler M, Potvin J (1994) Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 55: 50–59PubMedGoogle Scholar
  125. Tyrer PJ, Lee I, Edwards JG et al. (1980) Prognostic factors determining response to antidepressant drugs in psychiatric out-patients and general practice. J Affective Disord 2: 149–156CrossRefGoogle Scholar
  126. Tyrer P. (1985) Neurosis divisible? Lancet 1: 685PubMedCrossRefGoogle Scholar
  127. Tyrer P (1989) Classification of Neurosis. John Wiley & Sons, ChichesterGoogle Scholar
  128. Tyrer P, Tyrer J (1994) Antidepressive Drugs for Treatment of Anxiety Disorders - and Vice Versa. In: de Bor JA, Sitsen JM (eds) Handbook of Depression and Anxiety. A Biological Approach. Marcel Dekker, Inc. New York Basel Hong Kong 497–511Google Scholar
  129. Uhlenhuth EH, DeWit H, Baler MB et al. (1988) Risk and benefits of long-term benzodiazepine use. J Clin Psychopharmacol 8: 161–167PubMedCrossRefGoogle Scholar
  130. Üstün TB, Sartorius N (1995) An international study of psychosocial disorders in 14 countries: standadized assessmet of ill-defined problems in primary care: the background and rationale of the WHO Collaborative Project on „Psychological Problems in General Health Care“. In: Miranda J, Homann A, Atkinson C, Larson D (eds) Mental Disorders in Primary Health Care. Jossey-Bass Inc., San FranciscoGoogle Scholar
  131. Van Ameringen M, Mancini C, Streiner DL (1993) Fluoxetine efficacy in social phobia. J Clin Psychiatry 54: 27–32PubMedGoogle Scholar
  132. VanValkenburg C, Akiskal H, Puzantian V, Rosenthal T (1984) Anxious depressions: clinical, family history, and naturalistic outcome comparisons with panic and major depressive disorders. J Affect Disord 6: 67–82PubMedCrossRefGoogle Scholar
  133. Versiani M, Nardi AE, Mundin FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacothrapy in social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry. 161: 353–360PubMedCrossRefGoogle Scholar
  134. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R (1996) The long-term treat-ment of social phobia with moclobemide. International Clin Psychopharmacol 11: 3: 83–88CrossRefGoogle Scholar
  135. Volz HP, Möller HJ, Sturm Y (1994) Generalisierte Angsterkrankungen. Psychopharmakothe-rapie 1: 4: 101–106Google Scholar
  136. Wacker HR (1991) Angst und Depression: Descriptoren, Prädiktoren: Eine Querschnitts-und Verlaufsuntersuchung. Schweizer Nationalfonds, Schlußbericht. Gesuch-Nr. 32–9373 (3.995–0.87)Google Scholar
  137. Wakelin JS (1988) The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? Adv Biol Psychiatry 17: 70–83Google Scholar
  138. Westenberg HGM (1994) Ergebnisse einer multinationalen Placebo-kontrollierten Studie mit Clomipramin und Paroxetin in der Behandlung der Panikstörung. Vortrag SymposiumEurop.Facing Depression - des 7. AEP-Kongesses Kopenhagen in TW Neurologie/Psychiatrie, Sonderdruck 128: 698–698Google Scholar
  139. Westenberg HGM, Den Boer JA, Murphy DL (1996) Advances in the neurobiology of anxiety disorders. Wiley, Chichester New YorkGoogle Scholar
  140. Wittchen HU, von Zerssen D (1987) Verläufe behandelter und unbehandelter Depressionen und Angststörungen. - Eine klinisch-psychiatrische und epidemiologische Verlaufsuntersuchung. Springer, BerlinGoogle Scholar
  141. Wittchen HU (1991) Der Langzeitverlauf unbehandelter Angststörungen: Wie häufig sind Spontanremissionen. Verhaltenstherapie, Band I: 4: 273–283.Google Scholar
  142. Wittchen HU, Essau CA, von Zerssen D, Krieg CJ, Zaudig M (1992) Lifetime and six-month prevalent e of mental disorders in the Munich Follow-up-Study. European Archives of Psychiatry and Clinical Neurosciences 41: 247–258CrossRefGoogle Scholar
  143. Wittchen HU, Vossen A (1995) Implikationen von Komorbidität bei Angststörungen - Ein kritischer Überblick, Verhaltenstherapie 5:120–133CrossRefGoogle Scholar
  144. Wolfe BE, Maser JD (1994) Treatment of Panic Disorder. A Consensus Development Conference. Washington AP PressGoogle Scholar
  145. Woods JH, Katz JL, Winger G (1992) Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44: 155–186Google Scholar
  146. Woods S, Black D, Brown S, Asnis S, Potkin S, Hameedi F, Goddard A (1994) Fluvoxamine in the treatment of panic disorder in outpatients: double-blind, placebo-controlled study. Poster on the 19th Congress of the Collegium Internationale Neuropsychopharmacologicum, Washington DC, June 1994Google Scholar
  147. Wurthmann C, Klieser E, Lehmann E (1995) Pharmakotherapie generalisierter Angststörungen mit Fluspirilen. Psychopharmakotherapie 2: 3:118–122Google Scholar
  148. Zung W, Magruder-Habib K, Velez R, Alling W (1990) The comorbidity of anxiety and depression in general medical patients: a longitudinal study. J Clin Psychiatry 51: 77–80PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • R. J. Boerner
  • H. J. Möller

There are no affiliations available

Personalised recommendations